We are happy to respond to the questions raised by Peng and Du. As we described in our Methods,¹ we had to estimate the prevalence of hepatitis B virus (HBV) infection of various serostatuses [e.g. proportion with hepatitis B surface antigen (HBsAg) and hepatitis B e-antigen (HBeAg) dual-positive serostatus] in order to estimate the number of pregnant women at high risk of perinatal HBV transmission. The prevalence of HBsAg and HBeAg dual-positive serostatus was estimated by age groups. For women aged 15–29 years, the estimate was based on the 2014 serosurvey²; for women 30 years of age or older, the prevalence was based on the calculated age in 2014 by shifting 8 years of the participant’s age from the 2006 survey to reflect age-related changes over the 8-year period from 2006 to 2014.^1–3 The differences in percentages of those who were HBeAg-positive among 22–41 versus 30–49-year-olds in 2006 were assumed to be wholly due to seroconversion. In this reconstructed survey, the loss of HBeAg over time with ageing of the 2006 survey participants, as Peng and Du correctly point out, should be accounted for.

中文翻译：

---

应对：慢性乙型肝炎感染孕妇的抗病毒治疗

我们很高兴回答彭和杜提出的问题。正如我们在《方法》中所描述的^1，我们必须估计各种血清状态的乙型肝炎病毒（HBV）感染率[例如，与乙型肝炎表面抗原（HBsAg）和乙型肝炎电子抗原（HBeAg）双重阳性血清状态的比例]为了评估围产期HBV传播高危孕妇的数量。HBsAg和HBeAg双重阳性血清状况的发生率是按年龄段估算的。对于15-29岁的女性，此估算基于2014年的血清调查²; 对于30岁以上的女性，该患病率是基于2014年的计算年龄，将参与者的年龄从2006年调查的8岁转变为2006年至2014年这8年间与年龄相关的变化^{。1– 3} 2006年22-41岁和30-49岁人群中HBeAg阳性人群的百分比差异被认为完全是由于血清转化所致。正如Peng和Du正确指出的那样，在此重建的调查中，应考虑到2006年调查参与者的衰老导致HBeAg随时间的流逝。